The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 mol glycodeoxycholic acid (GDCA)/gram/hour and >2 mol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 mol GDCA/g/hr and >7 mol TDCA/g/hr when measured over 30 minutes.

The present invention relates to granules of active ingredient with double taste masking, wherein the double taste masking is achieved by a hot-melt compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and of glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and mixtures thereof, and a thermoplastic polymer that is soluble at a pH less than or equal to 5. The invention also relates to the method for producing these granules and to orodispersible tablets containing these coated granules.

An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.

The present invention relates to kinase inhibitor C.sub.8-C.sub.16 aliphatic sulfate salts, compositions containing kinase inhibitor C.sub.8-C.sub.16 aliphatic sulfate salts and uses thereof.

The present disclosure relates to naltrexone sustained release microparticle delivery systems for the treatment of diseases ameliorated by naltrexone. The injectable microparticle delivery system includes naltrexone encapsulated in biodegradable microparticles administered in a pharmaceutically acceptable vehicle.

The present invention provides for method of improving flowability and loose bulk density of functionalized natural- and/or synthetic calcium carbonate comprising material, to the use of such improved material in ready to use granules and thereof produced dispersible dosage forms.

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.

The instant disclosure is directed to a vaginal care composition that restores pH balance, and thereby reduces vaginal dryness, irritation, dyspareunia, post-coital bleeding, infections, vaginal and pelvic pain and increases vaginal lubrication. In some embodiments, the vaginal care composition comprises stem cell-derived exosomes (e.g., mesenchymal stem cell (MSC)-derived exosomes), an antioxidant and a pH buffer. Another aspect of the disclosure is directed to methods for improving vaginal health by administering the vaginal care composition of the instant disclosure.

The probiotic powder compositions comprising probiotic microorganisms encapsulated in nutritional rich cereal powder matrix. Encapsulation of probiotics in cereal powders offers nutritive and health benefits to the consumer. The present invention further includes methods of making and using the probiotic powder compositions of the invention. The powder compositions are stable, maintains the viability of probiotic microorganisms in various formulations.